1248
S. Lebrun et al. / Tetrahedron: Asymmetry 19 (2008) 1245–1249
and the product was purified by flash column chromatography on
silica gel using AcOEt–PE (20:80) as eluent to afford dienehydr-
azides 4 (352 mg, 49%) and 14 (340 mg, 44%) as a yellow oil.
J = 11.6 Hz, 1H, OCH2Ph), 4.63 (d, J = 11.6 Hz, 1H, OCH2Ph), 5.71
(dd, J = 1.9, 9.8 Hz, 1H, CH@), 6.28–6.34 (m, 1H, CH@), 7.21–7.35
(m, 5H, Harom). 13C NMR (CDCl3, 75 MHz): d 10.9, 22.8, 23.5, 24.1,
27.4, 51.9, 58.7, 58.8, 60.0, 72.5, 75.4, 80.6, 125.4, 127.7, 128.0,
129.0, 136.2, 138.4, 163.8. Anal. Calcd for C21H30N2O3: C, 70.36;
H, 8.44; N, 7.81. Found: C, 70.58; H, 8.49; N, 7.69.
4.3.1. (1R,2S)-(ꢀ)-N-[1-(Benzyloxymethyl)but-3-enyl]-N-(2-
methoxymethylpyrrolidin-1-yl)acrylamide 4
20
½aꢂD ¼ ꢀ32:5 (c 0.92, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.65–
1.89 (m, 4H, HSMP), 2.63–2.93 (m, 5H), 3.15–3.41 (m, 6H, HSMP),
3.79 (dd, J = 5.4, 9.5 Hz, 1H, CH2O), 4.11 (dd, J = 6.9, 9.5 Hz, 1H,
CH2O), 4.52 (s, 2H, OCH2Ph), 5.04–5.18 (m, 2H, Hvinyl), 5.59 (dd,
J = 2.3, 10.4 Hz, 1H, Hvinyl), 5.73–5.86 (m, 1H, Hvinyl), 6.30 (dd,
J = 2.3, 17.2 Hz, 1H, Hvinyl), 7.14 (dd, J = 10.5, 17.2 Hz, 1H, Hvinyl),
7.23–7.38 (m, 5H, Harom). 13C NMR (CDCl3, 75 MHz): d 21.2, 25.7,
35.4, 51.9, 56.3, 58.6, 58.8, 70.9, 73.2, 73.3, 117.4, 126.3, 127.5,
127.8, 128.3, 129.2, 135.4, 138.1, 169.3. Anal. Calcd for C21H30N2O3:
C, 70.36; H, 8.44; N, 7.81. Found: C, 70.29; H, 8.51; N, 8.02.
4.4.3. (6R,1R)-(+)-6-(1-Benzyloxypropyl)-5,6-dihydro-1H-
pyridin-2-one 16
20
½aꢂD ¼ þ15:1 (c 0.99, CHCl3); 1H NMR (CDCl3, 300 MHz): 0.98 (t,
J = 7.5 Hz, 3H, CH3), 1.43–1.61 (m, 2H, CH2), 2.11–2.24 (m, 1H,
CH2), 2.28–2.41 (m, 1H, CH2), 3.34–3.42 (m, 1H), 3.65–3.71 (m,
1H), 4.44 (d, J = 11.2 Hz, 1H, OCH2Ph), 4.66 (d, J = 11.2 Hz, 1H,
OCH2Ph), 5.91–5.98 (m, 2H, NH + CH@), 6.56–6.63 (m, 1H, CH@),
7.30–7.39 (m, 5H, Harom). 13C NMR (CDCl3, 75 MHz): d 7.8, 21.7,
26.5, 52.4, 71.5, 81.4, 124.8, 127.8, 127.9, 128.6, 137.6, 139.7,
166.2. Anal. Calcd for C15H19NO2: C, 73.44; H, 7.81; N, 5.71. Found:
C, 73.33; H, 7.61; N, 5.66.
4.3.2. (1R,1R,2S)-(ꢀ)-N-[1-(1-Benzyloxypropyl)but-3-enyl]-N-
(2-methoxymethylpyrrolidin-1-yl)acrylamide 14
20
½aꢂD ¼ ꢀ9:3 (c 1.54, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.02 (t,
4.5. General procedure for the synthesis of piperidin-2-ones 9,
10 and 17
J = 7.3 Hz, 3H, CH3), 1.41–1.93 (m, 6H), 2.47–2.53 (m, 1H), 2.75–
3.18 (m, 5H), 3.20–3.35 (m, 5H), 4.16–4.24 (m, 1H), 4.48 (d,
J = 11.0 Hz, 1H, OCH2Ph), 4.52 (d, J = 11.0 Hz, 1H, OCH2Ph), 5.03–
5.18 (m, 2H, Hvinyl), 5.61 (dd, J = 2.4, 10.5 Hz, 1H, Hvinyl), 5.72–
5.85 (m, 1H, Hvinyl), 6.33 (dd, J = 2.4, 17.1 Hz, 1H, Hvinyl), 7.13 (dd,
J = 10.5, 17.1 Hz, 1H, Hvinyl), 7.24–7.39 (m, 5H, Harom). 13C NMR
(CDCl3, 75 MHz): d 9.2, 21.5, 25.4, 26.7, 36.2, 51.8, 58.9, 59.0,
60.2, 73.7, 74.1, 79.2, 117.0, 126.3, 127.3, 128.0, 128.1, 136.1,
136.3, 137.2, 169.6. Anal. Calcd for C23H34N2O3: C, 71.47; H, 8.87;
N, 7.25. Found: C, 71.61; H, 8.59; N, 7.03.
A solution of enehydrazides 8, 15, 16 (1.0 mmol) in EtOH
(15 mL) was stirred with activated Pd/C (10%, 15 mg) under H2 (1
atm) at rt for 12 h at which time TLC indicated complete consump-
tion of the starting material. The mixture was filtered on a pad of
Celite that was further eluted with EtOH (30 mL) and CH2Cl2
(30 mL). The filtrate was concentrated under vacuum and purifica-
tion of the residue by column chromatography on silica gel using
AcOEt–PE (80:20) as eluent gave piperidin-2-ones 9 (218 mg,
90%), 10 (256 mg, 95%) and 17 (144 mg, 92%) as a yellow oil.
4.4. General procedure for the ring-closing metathesis of
dienehydrazides 4, 14
4.5.1. (6R,2S)-(ꢀ)-6-Hydroxymethyl-1-(2-methoxy-
methylpyrrolidin-1-yl)piperidin-2-one 9
20
A solution of the dienehydrazides 4 and 14 (1 mmol) and the
first generation Grubbs catalyst (0.05 mmol, 5 mol %) in anhydrous
CH2Cl2 (10 mL) was refluxed for 12 h under Ar (reaction monitored
by TLC). The reaction mixture was concentrated under vacuum and
the residue was purified by column chromatography on silica gel
using AcOEt–PE (40:60) as eluent.
½aꢂD ¼ ꢀ23:4 (c 0.80, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.33–
1.81 (m, 6H), 1.94–2.38 (m, 4H), 3.07–3.15 (m, 1H), 3.24–3.31
(m, 5H, HSMP), 3.35 (dd, J = 3.6, 9.7 Hz, 1H), 3.48–3.56 (m, 2H),
3.64–3.74 (m, 2H), 3.80–3.85 (m, 1H). 13C NMR (CDCl3, 75 MHz):
d 19.2, 23.4, 27.1, 27.3, 33.7, 53.5, 58.8, 60.3, 64.1, 67.3, 75.1,
168.9. Anal. Calcd for C12H22N2O3: C, 59.48; H, 9.15; N, 11.56.
Found: C, 59.66; H, 8.96; N, 11.44.
Ring-closing metathesis of 4 afforded enehydrazide 8 (244 mg,
74%) as a yellow oil.
For the ring-closing metathesis of 14, chromatographic treat-
ment furnished two fractions containing enehydrazide 15
(242 mg, 45%) as a yellow oil and enamide 16 (136 mg, 37%) as a
colorless oil.
4.5.2. (6R,1R,2S)-(+)-6-(1-Hydroxypropyl)-1-(2-methoxy-
methylpyrrolidin-1-yl)piperidin-2-one 10
20
½aꢂD ¼ þ24:1 (c 0.54, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.00 (t,
J = 7.3 Hz, 3H, CH3), 1.43–1.91 (m, 9H), 2.15–2.22 (m, 1H), 2.31 (t,
J = 6.5 Hz, 2H, CH2C@O), 3.12–3.21 (m, 2H, HSMP), 3.26–3.44 (m, 6H,
4.4.1. (6R,2S)-(ꢀ)-6-Benzyloxymethyl-1-(2-methoxymethyl-
pyrrolidin-1-yl)-5,6-dihydro-1H-pyridin-2-one 8
HSMP), 3.61–3.68 (m, 1H), 4.05–4.12 (m, 1H), 6.24 (br s, 1H, OH).
13C NMR (CDCl3, 75 MHz): d 9.4, 19.5, 23.4, 26.1, 27.1, 27.4, 34.3,
50.3, 58.7, 60.3, 65.2, 75.4, 75.9, 170.6. Anal. Calcd for C14H26N2O3:
C, 62.19; H, 9.69; N, 10.36. Found: C, 61.94; H, 9.87; N, 10.21.
20
½aꢂD ¼ ꢀ7:0 (c 0.30, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.48–
1.53 (m, 1H, HSMP), 1.64–1.77 (m, 1H, HSMP), 1.93–2.11 (m, 2H,
HSMP), 2.52–2.71 (m, 2H, CH2), 3.04–3.13 (m, 1H), 3.31–3.36 (m,
6H, HSMP), 3.52–3.65 (m, 2H, HSMP), 3.74–3.96 (m, 2H, CH2O),
4.50 (d, J = 11.8 Hz, 1H, OCH2Ph), 4.56 (d, J = 11.8 Hz, 1H, OCH2Ph),
5.79 (m, 1H, Hvinyl), 6.31–6.38 (m, 1H, Hvinyl), 7.24-7.37 (m, 5H,
4.5.3. (6R,1R)-(+)-6-(1-Hydroxypropyl)piperidin-2-one 17
20
½aꢂD ¼ þ15:3 (c 0.84, CHCl3); 1H NMR (CDCl3, 300 MHz): 1.02 (t,
J = 7.3 Hz, 3H, CH3), 1.31–1.44 (m, 2H, CH2), 1.53–1.70 (m, 2H, CH2),
H
arom). 13C NMR (CDCl3, 75 MHz): d 23.1, 26.6, 27.2, 52.8, 58.9,
1.88–2.01 (m, 2H, CH2), 2.17–2.29 (m, 1H, CH2), 2.35–2.48 (m, 1H,
60.4, 60.7, 68.9, 73.3, 76.5, 125.8, 127.6, 127.7, 128.4, 137.2,
138.0, 162.9. Anal. Calcd for C19H26N2O3: C, 69.06; H, 7.93; N,
8.48. Found: C, 69.17; H, 8.09; N, 8.62.
CH2), 3.19–3.31 (m, 2H), 4.04 (br s, 1H, OH), 6.99 (br s, 1H, NH). 13
C
NMR (CDCl3, 75 MHz): d 9.4, 19.9, 25.0, 26.3, 31.1, 57.4, 76.0, 172.8.
Anal. Calcd for C8H15NO2: C, 61.12; H, 9.62; N, 8.91. Found: C,
61.26; H, 9.83; N, 8.74.
4.4.2. (6R,1R,2S)-(+)-6-(1-Benzyloxypropyl)-1-(2-methoxy-
methylpyrrolidin-1-yl)-5,6-dihydro-1H-pyridin-2-one 15
4.6. (2S,2R)-(ꢀ)-1-(2-Methoxymethylpyrrolidin-1-yl)-6-oxo-
20
½aꢂD ¼ þ24:7 (c 0.72, CHCl3); 1H NMR (CDCl3, 300 MHz): 0.98 (t,
piperidin-2-carbaldehyde 3
J = 7.2 Hz, 3H, CH3), 1.23–1.37 (m, 2H, CH2), 1.52–1.91 (m, 4H,
HSMP), 2.14–2.25 (m, 1H), 2.51–2.68 (m, 2H, CH2), 3.16–3.35 (m,
A solution of DMSO (320 mg, 4.1 mmol) in CH2Cl2 (2 mL) was
6H, SMP), 3.65–3.71 (m, 1H), 3.78–4.03 (m, 2H), 4.52 (d,
H
added dropwise at ꢀ78 °C to
a solution of oxalyl chloride